Our presenters were:
The Stanford Desmoid Tumor Board.
Kristen Ganjoo, MD
Associate Professor of Medicine (Oncology) & Director
Stanford Sarcoma Program, Stanford University Medical Center
Treatment of desmoid tumors with magnetic resonance imaging guided High Intensity Focused Ultrasound (HIFU) and cryoablation.
Pejman Ghanouni, MD, PhD
Assistant Professor of Radiology
Stanford School of Medicine
Update on the recent launch of Phase I trial for Tegavivint.
Casey Cunningham, MD
Chief Medical Officer
Iterion Therapeutics (formerly Beta Cat Pharmaceuticals, Inc.)
Targeted treatments for desmoid tumors.
Shivaani Kummar, MD, FACP
Director of the Translational Oncology and Phase I Clinical Research Programs
Stanford University
An update on Phase III trial of Nirogacestat.
L. Mary Smith, PhD
VP of Clinical Research & Development
SpringWorks Therapeutics
The pathology of desmoid tumors.
Matthew van de Rijn, MD, PhD
Professor, Department of Pathology
Stanford University Medical Center
The DTRF’s accomplishments.
Jeanne Whiting
President and Co-Founder of DTRF
Desmoid tumors: Understanding treatment options in 2019.
Breelyn Wilky, MD
Associate Professor & Director of Sarcoma Translational Research
University of Colorado School of Medicine
Chris Barry
FAP and desmoid tumor patient
